Efficacy and Safety of AM-111 in the Treatment of Acute Unilateral Sudden Deafness—A Double-blind, Randomized, Placebo-controlled Phase 3 Study

OBJECTIVE: To confirm the efficacy and safety of AM-111 (brimapitide), a cell-penetrating c-Jun N-terminal Kinase (JNK) inhibitor, in patients suffering from severe to profound acute unilateral idiopathic sudden sensorineural hearing loss (ISSNHL). STUDY DESIGN: Prospective, double-blind, randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Staecker, Hinrich, Jokovic, Galina, Karpishchenko, Sergey, Kienle-Gogolok, Andrea, Krzyzaniak, Andrzej, Lin, Chia-Der, Navratil, Pavel, Tzvetkov, Ventzislav, Wright, Nida, Meyer, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Sensorineural Hearing Loss & Tinnitus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553962/
https://www.ncbi.nlm.nih.gov/pubmed/31083077
http://dx.doi.org/10.1097/MAO.0000000000002229

Ejemplares similares

Ejemplares similares